The price of Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) shares last traded on Wall Street rose 9.82% to $0.34.
AGLE stock price is now -27.56% away from the 50-day moving average and -42.35% away from the 200-day moving average. The market capitalization of the company currently stands at $24.34M.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
With the price target of $12, Piper Sandler recently initiated with Overweight rating for Aeglea BioTherapeutics Inc. (NASDAQ: AGLE). On March 21, 2019, JP Morgan recently initiated its ‘Overweight’ rating on the stock quoting a target price of $14, while ‘Wells Fargo’ rates the stock as ‘Market Perform’.
In other news, Souza Marcio, Director bought 90,000 shares of the company’s stock on Aug 25. The stock was bought for $50,472 at an average price of $0.56. Upon completion of the transaction, the Director now directly owns 90,000 shares in the company, valued at $30600.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 08, Chief Commercial Officer Hanley Jr. Michael Conick bought 28,200 shares of the business’s stock. A total of $20,022 was incurred on buying the stock at an average price of $0.71. This leaves the insider owning 36,200 shares of the company worth $12308.0. A total of 0.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in AGLE stock. A new stake in Aeglea BioTherapeutics Inc. shares was purchased by PURA VIDA INVESTMENTS, LLC during the first quarter worth $357,000. SPHERA FUNDS MANAGEMENT LTD. invested $150,000 in shares of AGLE during the first quarter. In the first quarter, BRIDGEWAY CAPITAL MANAGEMENT, LLC acquired a new stake in Aeglea BioTherapeutics Inc. valued at approximately $51,000. EXODUSPOINT CAPITAL MANAGEMENT, LP acquired a new stake in AGLE for approximately $36,000. SUSQUEHANNA INTERNATIONAL GROUP, LLP purchased a new stake in AGLE valued at around $17,000 in the second quarter. In total, there are 79 active investors with 78.80% ownership of the company’s stock.
A candlestick chart of Aeglea BioTherapeutics Inc. (NASDAQ: AGLE) showed a price of $0.3200 on Thursday morning. During the past 12 months, Aeglea BioTherapeutics Inc. has had a low of $0.30 and a high of $3.17. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 4.20, and a quick ratio of 4.20. The fifty day moving average price for AGLE is $0.4694 and a two-hundred day moving average price translates $0.5897 for the stock.
The latest earnings results from Aeglea BioTherapeutics Inc. (NASDAQ: AGLE) was released for Sep, 2022. According to the Biotechnology Company, earnings per share came in at -$0.19, beating analysts’ expectations of -$0.23 by 0.04. This compares to -$0.31 EPS in the same period last year. The company reported revenue of $0.17 million for the quarter, compared to $3.64 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -95.39 percent. For the current quarter, analysts expect AGLE to generate $60k in revenue.
Aeglea BioTherapeutics Inc.(AGLE) Company Profile
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company’s lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company’s preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Leave a Reply